CF PharmTech, Inc. (HKG:2652)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
21.70
-0.76 (-3.38%)
At close: Apr 29, 2026
Market Cap 9.24B
Revenue (ttm) 481.31M
Net Income (ttm) 2.77M
Shares Out 411.35M
EPS (ttm) 0.01
PE Ratio 3,340.95
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,070,000
Average Volume 642,830
Open 22.16
Previous Close 22.46
Day's Range 21.50 - 22.88
52-Week Range 20.30 - 48.80
Beta n/a
RSI 39.60
Earnings Date Mar 30, 2026

About CF PharmTech

CF PharmTech, Inc. engages in research and development, production, and sale of respiratory drugs in the field of respiratory diseases in China. It offers Shufeimin, an azelastine hydrochloride and fluticasone propionate nasal spray; ChangQi, a budesonide inhalation suspension solution; ChangShu, a salbutamol sulfate inhalation solution; and piezoelectric mesh nebulizer, electric nasal cleaner, BFS hypertonic and physiological seawater nasal cleansing fluid products under the ChangShu name. The company also develops products for the treatment o... [Read more]

Sector Healthcare
Founded 2007
Employees 605
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2652
Full Company Profile

Financial Performance

In 2025, CF PharmTech's revenue was 432.52 million, a decrease of -28.83% compared to the previous year's 607.75 million. Earnings were 2.49 million, a decrease of -88.22%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.